Ascendis Pharma A (ASND) Gross Margin (2021 - 2026)

Ascendis Pharma A has disclosed Gross Margin across 6 years of filings, most recently posting 92.9% for Q1 2026.

• Gross Margin for Q1 2026 came in at 92.9%, up 1025.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 81.6% (up 1129.0% YoY), and the FY2025 annual result was 86.82%, down 190.0% from the prior year.
• Gross Margin came in at 92.9% for Q1 2026 at Ascendis Pharma A, up from 68.52% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 92.9% in Q1 2026 to a low of 37.81% in Q1 2022.
• The 5-year median for Gross Margin is 80.63% (2024), against an average of 76.29%.
• Peak annual rise in Gross Margin reached 7591 bps in 2022, while the deepest fall reached 6219 bps in 2022.
• Ascendis Pharma A's Gross Margin stood at 77.68% in 2022, then tumbled by 37 bps to 48.66% in 2023, then jumped by 30 bps to 63.34% in 2024, then gained by 8 bps to 68.52% in 2025, then surged by 36 bps to 92.9% in 2026.
• The last three Gross Margin figures came in at 92.9% (Q1 2026), 68.52% (Q4 2025), and 89.54% (Q3 2025), per Business Quant data.